What if the key to understanding Alzheimer's disease was hiding inside a rare childhood illness? That's exactly what researchers at the University of California San Diego discovered — and it could change how we fight brain degeneration.
In a study published in the journal Immunity, scientists found that the same cellular mechanism drives brain damage in both Sanfilippo syndrome type A and Alzheimer's disease. Sanfilippo syndrome type A, also called MPS IIIA, is a rare genetic disorder that strikes children. Because of a single faulty gene, their brains cannot break down waste properly. The buildup causes seizures, dementia, and early death. Alzheimer's disease, which affects millions of older adults worldwide, shares similar features — memory loss and cognitive decline — but has always seemed like a very different problem.
"It gave us a really clear framework to study what we see in common neurodegenerative diseases and try to figure out mechanisms that are causing them," said Christopher Balak, Ph.D., a postdoctoral researcher at UC San Diego who led the study.
The team zeroed in on microglia — the brain's dedicated immune cells. In children with MPS IIIA, these cells become clogged with fats and proteins as they try (and fail) to clean up the waste. The microglia swell up, lose their ability to protect neurons, and eventually contribute to brain damage. The researchers identified a family of proteins called MITF/TFE that act like master genetic switches. When the cells' cleanup systems become overwhelmed, these switches flip, changing the microglia's entire program. At first, this change helps. But over time, the response becomes harmful, fueling inflammation that kills neurons.
Here's the surprising part: the exact same switches flip on in the microglia of people with Alzheimer's disease. That means the same internal breakdown happening in a child's brain with MPS IIIA may also be happening in the aging brains of Alzheimer's patients.
Most scientists have believed that Alzheimer's damage starts from outside the cell, triggered by amyloid plaques. But this research suggests the problem can begin from inside the cell.
"We know lysosomes alone are sufficient to cause neurodegeneration from rare disorders like MPS IIIA," Balak said. "The same thing could be happening in, or at least contributing to, major diseases like Alzheimer's disease."
The discovery opens a new avenue for drug development. Instead of targeting receptors on the cell surface — the approach most Alzheimer’s drugs take — researchers could aim at these genetic switches inside the cell. The team also found that microglia try to contain the damage early, before becoming overwhelmed. That timing matters: treating patients before the switches flip could be the most effective approach, whether through enzyme replacement therapy or new cell-based treatments.
For families affected by Sanfilippo, the findings offer a dual hope — not only a possible treatment for their children, but a potential path toward understanding and slowing a disease that touches millions of older adults worldwide.